Liposomal encapsulation of doxorubicin and targeted delivery of the compound to EGFR overexpressing breast cancer cells was hypothesized to improve efficacy while at the same time causing less safety signals in comparison to free and untargeted application. The gene discussed is EGFR; the disease is breast carcinoma.